Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Axitinib
Drug ID BADD_D00193
Description Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Indications and Usage Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
Marketing Status approved; investigational
ATC Code L01EK01
DrugBank ID DB06626
KEGG ID D03218
MeSH ID D000077784
PubChem ID 6450551
TTD Drug ID D01ZRI
NDC Product Code 0069-0145; 54893-0032; 68554-0088; 63539-026; 82920-028; 0069-0151; 65344-0033; 63539-044; 54893-0043
UNII C9LVQ0YUXG
Synonyms Axitinib | AG 013736 | AG013736 | AG-013736 | Inlyta
Chemical Information
Molecular Formula C22H18N4OS
CAS Registry Number 319460-85-0
SMILES CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatobiliary disease09.01.08.003--Not Available
Retinal vascular thrombosis24.01.07.001; 06.10.01.004--Not Available
Metastasis16.22.01.0010.000381%Not Available
Renal impairment20.01.03.0100.005876%Not Available
Sinus disorder22.04.06.0020.000571%
Haemorrhagic diathesis24.07.01.020; 01.01.03.0030.000112%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.001992%Not Available
Osteonecrosis of jaw15.02.04.010; 24.04.05.0050.000895%
Infusion site extravasation12.07.05.008; 08.02.05.007--
Thyroid cancer16.24.03.001; 05.02.05.0010.000302%Not Available
Pharyngeal disorder22.04.05.0070.000627%Not Available
Organising pneumonia22.01.02.0080.000224%Not Available
Type 1 diabetes mellitus14.06.01.010; 10.04.08.007; 05.06.01.0100.000168%Not Available
Oral disorder07.05.01.0050.000492%Not Available
Skin mass23.07.04.0140.000437%Not Available
Renal cell carcinoma16.08.02.002; 20.01.04.0030.011249%Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.0080.000627%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.006078%
Acute kidney injury20.01.03.016--
Skin sensitisation23.03.03.052; 10.02.01.0380.000381%Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.001623%
Drug-induced liver injury09.01.07.023; 12.03.01.044--Not Available
Faeces soft07.01.03.0080.000358%Not Available
Noninfective gingivitis07.09.13.0160.000571%Not Available
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.0070.000246%Not Available
Frustration tolerance decreased19.04.02.016--Not Available
Brain neoplasm malignant17.20.04.002; 16.30.04.0020.000112%Not Available
Diverticulum intestinal haemorrhagic24.07.02.043; 07.10.01.0030.000224%Not Available
Eczema asteatotic23.03.04.0250.000112%Not Available
Grief reaction19.23.01.003--Not Available
The 15th Page    First    Pre   15 16 17    Next   Last    Total 17 Pages